About me
Polly leads Oncology business development activities, including search and evaluation, transactions and alliance management. She also leads the development and execution of a fully integrated Oncology R&D BD strategy. Within this role, Polly has overseen the in-licensing of multiple small molecules and antibody drug conjugates, as well as the acquisition of Gracell Biotechnologies and Fusion Pharmaceuticals, bringing in new therapeutics and complementary capabilities that are pivotal for advancing AstraZeneca’s Oncology strategy.
Polly is a highly experienced leader with nearly 20 years’ experience in the industry, focussed on Oncology across business development, strategy, analytics and finance. With deep disease expertise and strong leadership skills, she previously held roles as VP Head of Strategy, where she led a team of 80+ people, and Head of Tumour Strategy for the Oncology Business Unit at AstraZeneca.
After earning a bachelor’s degree in maths and physics from the University of Bristol, Polly qualified as a Chartered Management Accountant while working as a Business Analyst in finance at AstraZeneca. She has studied and worked in the UK, France and USA, and currently resides in Boston, MA.